Alzheimer Disease

Featured Article
Early findings suggest donanemab may slow cognitive decline in patients with early Alzheimer’s disease, according to results of a randomized, phase 2 trial.
Researchers aimed to shed light on COVID-19 risks, outcomes, and disparities among US individuals with dementia.
In a new study, researchers investigated the prevalence of adverse financial events among Medicare beneficiaries with Alzheimer disease and related dementias (ADRD) in the years before and after diagnosis compared with demographically similar beneficiaries without ADRD.
New findings presented at the Radiological Society of North America’s Annual Meeting indicate that anxiety may play a role in faster progression to Alzheimer disease among patients with mild cognitive impairment.
New data presented at the Alzheimer’s Association International Conference indicate that measuring levels of this biomarker in plasma and cerebrospinal fluid can detect Alzheimer disease with high accuracy.
In a study of nearly 1.5 million people, researchers aimed to determine the impact of infections on the risk of mortality among people with or without dementia. The findings were presented at the Alzheimer’s Association International Conference.
Influenza vaccination may be a “promising, readily available candidate” for the prevention of Alzheimer disease, according to new findings presented at the Alzheimer’s Association International Conference.
Despite known, independent associations of hearing loss and vision loss with dementia, less is known about the relationship between dual sensory impairment and dementia risk. Researchers aimed to assess this further using data from the Gingko Evaluation of Memory Study.
The FDA has granted a landmark approval to an intravenous injection for the imaging of tau pathology among patients with cognitive impairment being evaluated for Alzheimer disease.
After reviewing data from 4500 MESA participants, researchers determined whether tracking cross-sectionally measured NT-proBNP over 3.2 years is related to incident dementia. Find out more about this new analysis.
Many patients with Alzheimer disease may become confused, anxious, aggressive, agitated, or restless consistently in the late afternoon or early evening. Do you know when this symptom, known as sundowning, tends to peak?